<article id="body_of_evidence" class="slide" data-ag-slide-name="Body of evidence">
    <div class="basic">
      <h1 id="wealth_of_evidence_pre_header" data-ag-editable="Body of evidence Pre Main Title">Strong body of evidence</h1>
      <h1 id="wealth_of_evidence_post_header" class="wealth_of_evidence_hidden_content" data-ag-editable="Body of evidence Post Main Title">Currently published phase III trial data on lipegfilgrastim</h1>
      <div id="wealth_of_evidence_pre_top_copy" class="body_of_evidence_top_copy" data-ag-editable="Body of evidence Pre Top Copy"><strong>More than 9 tumour types</strong> and <strong>several chemotherapy regimens</strong> investigated in <strong>more than 30 clinical trials</strong> with Neulasta<sup>®</sup> worldwide<sup>1–3</sup></div>
      <div id="wealth_of_evidence_post_top_copy" class="body_of_evidence_top_copy wealth_of_evidence_hidden_content" data-ag-editable="Body of evidence Post Top Copy"><strong>Two tumour types and chemotherapy regimens</strong> investigated in lipegfilgrastim trials<sup>1</sup></div>
      <div id="body_of_evidence_map_btn"></div>
      <div id="body_of_evidence_circles_holder_strong">
         <div id="body_of_evidence_circle1" class="body_of_evidence_blue_circle" data-ag-editable="Body of evidence Strong Circle 1">NHL</div>
         <div id="body_of_evidence_circle2" class="body_of_evidence_blue_circle body_of_evidence_circle_two_lines" data-ag-editable="Body of evidence Strong Circle 2">Hodgkin's disease</div>
         <div id="body_of_evidence_circle3" class="body_of_evidence_green_circle" data-ag-editable="Body of evidence Strong Circle 3">NSCLC</div>
         <div id="body_of_evidence_circle4" class="body_of_evidence_green_circle" data-ag-editable="Body of evidence Strong Circle 4">Breast</div>
         <div id="body_of_evidence_circle5" class="body_of_evidence_green_circle" data-ag-editable="Body of evidence Strong Circle 5">SCLC</div>
         <div id="body_of_evidence_circle6" class="body_of_evidence_green_circle" data-ag-editable="Body of evidence Strong Circle 6">Ovarian</div>
         <div id="body_of_evidence_circle7" class="body_of_evidence_green_circle" data-ag-editable="Body of evidence Strong Circle 7">Colorectal</div>
         <div id="body_of_evidence_circle8" class="body_of_evidence_green_circle body_of_evidence_circle_two_lines" data-ag-editable="Body of evidence Strong Circle 8">Paediatric<br />sarcoma</div>  
         <div id="body_of_evidence_circle9" class="body_of_evidence_blue_circle" data-ag-editable="Body of evidence Strong Circle 9">AML</div>
         <div id="body_of_evidence_circle10" class="body_of_evidence_blue_circle body_of_evidence_circle_two_lines" data-ag-editable="Body of evidence Strong Circle 10">Multiple myeloma</div>
      </div>
      <div id="body_of_evidence_circles_holder_weak" class="wealth_of_evidence_hidden_content">
         <div id="body_of_evidence_weak_circle1" class="body_of_evidence_grey_circle" data-ag-editable="Body of evidence Weak Circle 1">Breast</div>
         <div id="body_of_evidence_weak_circle2" class="body_of_evidence_grey_circle" data-ag-editable="Body of evidence Weak Circle 2">Lung</div>
      </div>
      <div id="body_of_evidence_blue_guy"></div>
    </div>
    <!-- Pop Up Bits -->
    <!-- Strong PopUp 1 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_nhl">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_nav_holder">
             <div id="body_of_evidence_popup_strong1_up" class="body_of_evidence_popup_nav_up_arrow"></div>
             <div id="body_of_evidence_popup_strong1_down" class="body_of_evidence_popup_nav_down_arrow"></div>
          </div>
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 1 Header">Non-Hodgkin’s lymphoma <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 1 Table Header">
            <tr>
               <th width="255">Investigated regimen(s)<br />(among others)</th>
               <th width="83">No. in study</th>
               <th width="273">Primary endpoint</th>
               <th width="144">Reference</th>
            </tr>
         </table>
         <div id="body_of_evidence_popup_strong1">
            <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 1 Table">
               <tr>
                  <td width="270" class="body_of_evidence_popup_first_col" rowspan="3">R-CHOP</td>
                  <td width="85">50</td>
                  <td width="270">Feasibility and toxicity of R-CHOP-14 + pegfilgrastim</td>
                  <td width="130">Brusamolino E <em>et al</em>. Haematologica 2006; 91:496-502</td>
               </tr>
               <tr>
                  <td>60</td>
                  <td>% of cycles given at planned dose on time, % receiving planned dose on time, clinical response</td>
                  <td>Lopez A <em>et al</em>. Blood 2004;104(11):A3311</td>
               </tr>
               <tr>
                  <td>279<br />(77 with NHL)</td>
                  <td>Duration of severe (grade 4) neutropenia in cycle 1</td>
                  <td>Burris HA <em>et al</em>. J Oncol Pract. 2010; 6:133-40</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col" rowspan="3">CHOP</td>
                  <td>30</td>
                  <td>% receiving full dose chemotherapy on schedule</td>
                  <td>Wolf M <em>et al</em>.. Leuk Lymphoma. 2006; 47:2344-50</td>
               </tr>
               <tr>
                  <td>30</td>
                  <td>PK profile</td>
                  <td>George S <em>et al</em>. Leuk Lymphoma. 2003; 44:1691-6</td>
               </tr>
               <tr>
                  <td>50</td>
                  <td>Duration of severe (grade 4) neutropenia in cycle 1</td>
                  <td>Grigg A <em>et al</em>. Leuk Lymphoma 2003; 44:1503-08</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">ESHAP</td>
                  <td>66</td>
                  <td>Duration of severe (grade 4) neutropenia in cycle 1</td>
                  <td>Vose JM <em>et al</em>. J Clin Oncol 2003; 21(3):514-19</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">ICE</td>
                  <td>92</td>
                  <td>Mean yield of CD34+ cells</td>
                  <td>Russell N, <em>et al</em>. Haematologica 2008; 93(3):405–12</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">Various</td>
                  <td>852<br />(146 with NHL)</td>
                  <td>Incidence of FN</td>
                  <td>Balducci L <em>et al</em>. Oncologist 2007; 12:1416-24</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_bottom_left" rowspan="2">&nbsp;</td>
                  <td>2249<br />(325 with NHL)</td>
                  <td>Incidence of neutropenic hospitalisations and chemotherapy dose delays or reductions</td>
                  <td>Ozer H <em>et al</em>. Oncologist 2007; 12:484-94</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_total_col">&gt;900<br />total</td>
                  <td>&nbsp;</td>
                  <td>&nbsp;</td>
               </tr>
            </table>
         </div>
       </div>
    </div>
    <!-- Strong PopUp 1 Ends -->
    <!-- Strong PopUp 2 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_hodgkins">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 2 Header">Hodgkin’s Disease (HD) <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 2 Table Header">
            <tr>
               <th width="237">Investigated regimen(s)<br />(among others)</th>
               <th width="99">No. in study</th>
               <th width="283">Primary endpoint</th>
               <th width="136">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 2 Table">
            <tr>
               <td width="249" class="body_of_evidence_popup_first_col">BEACOPP</td>
               <td width="92">41</td>
               <td width="284">Full dose of chemotherapy on schedule</td>
               <td width="130">Engert A <em>et al</em>. Haematologica 2006; 91:546-9</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col">Various</td>
               <td>2249<br />(46 with Hodgkin's lymphoma)</td>
               <td>Incidence of neutropenic hospitalisations and chemotherapy dose delays or reductions</td>
               <td>Ozer H <em>et al</em>. Oncologist 2007; 12:484-94</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_bottom_left">&nbsp;</td>
               <td class="body_of_evidence_popup_total_col">&gt;80<br />total</td>
               <td>&nbsp;</td>
               <td>&nbsp;</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 2 Ends -->
    <!-- Strong PopUp 3 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_nsclc">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 3 Header">NSCLC <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 3 Table Header">
            <tr>
               <th width="233">Investigated regimen(s)<br />(among others)</th>
               <th width="103">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 3 Table">
            <tr>
               <td width="219" class="body_of_evidence_popup_first_col">Carboplatin/docetaxel</td>
               <td width="107">279<br />(90 with NSCLC)</td>
               <td width="299">Duration of severe (grade 4) neutropenia in cycle 1</td>
               <td width="130">Burris HA <em>et al</em>. J Oncol Pract 2010; 6:133-40</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col">Carboplatin/paclitaxel<br />or<br />carboplatin/docetaxel</td>
               <td>149</td>
               <td>Incidence of grade 3/4 neutropenia</td>
               <td>Smith F <em>et al</em>. J Clin Oncol 2005; 23(16S):A8173</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col" rowspan="2">Carboplatin/paclitaxel</td>
               <td>13</td>
               <td>PK/PD</td>
               <td>Johnston E <em>et al</em>. J Clin Oncol 2000; 18:2522-28</td>
            </tr>
            <tr>
               <td>61<br />(23 with NSCLC)</td>
               <td>Peak peripheral CD34+ cell count in cycle 1</td>
               <td>Willis F <em>et al</em>. Bone Marrow Transplant. 2009; 43:927-34</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col">Various</td>
               <td>2249 <br />(265 NSCLC)</td>
               <td>Incidence of neutropenic hospitalisations and chemotherapy dose delays or reductions</td>
               <td>Ozer H <em>et al</em>. Oncologist 2007; 12:484-94</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_bottom_left">&nbsp;</td>
               <td class="body_of_evidence_popup_total_col">&gt500<br />total</td>
               <td>&nbsp;</td>
               <td>&nbsp;</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 3 Ends -->
    <!-- Strong PopUp 4 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_breast">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_nav_holder">
             <div id="body_of_evidence_popup_strong4_up" class="body_of_evidence_popup_nav_up_arrow"></div>
             <div id="body_of_evidence_popup_strong4_down" class="body_of_evidence_popup_nav_down_arrow"></div>
          </div>
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 4 Header">Breast <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 4 Table Header">
            <tr>
               <th width="249">Investigated regimen(s)<br />(among others)</th>
               <th width="87">No. in study</th>
               <th width="278">Primary endpoint</th>
               <th width="141">Reference</th>
            </tr>
         </table>
         <div id="body_of_evidence_popup_strong4">
            <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 4 Table">
               <tr>
                  <td width="260" class="body_of_evidence_popup_first_col" rowspan="3">AT</td>
                  <td width="86">154</td>
                  <td width="279">Duration of severe (grade 4) neutropenia in cycle 1</td>
                  <td width="130">Holmes FA <em>et al</em>. Ann Oncol 2002;13: 903-9</td>
               </tr>
               <tr>
                  <td>310</td>
                  <td>Duration of severe (grade 4) neutropenia in cycle 1</td>
                  <td>Holmes FA <em>et al</em>. J Clin Oncol 2002; 20: 727-31.</td>
               </tr>
               <tr>
                  <td>157</td>
                  <td>Duration of severe (grade 4) neutropenia in cycle 1</td>
                  <td>Green MD <em>et al</em>. Ann Oncol 2003; 14: 29-35.</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">Docetaxel</td>
                  <td>928</td>
                  <td>% developing FN</td>
                  <td>Vogel CL <em>et al</em>. J Clin Oncol. 2005 23:1178-84.</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">FEC 100</td>
                  <td>60</td>
                  <td>% experiencing a neutropenic event in cycle 1</td>
                  <td>Romieu G <em>et al</em>. Crit Rev Oncol Hematol. 2007;64:64-72.</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">CMF</td>
                  <td>58</td>
                  <td>% receiving ≥85% chemotherapy RDI</td>
                  <td>Mattioli R <em>et al</em>. Clin Transl Oncol. 2009 11:842-8.</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col" rowspan="2">AC&gt;T</td>
                  <td>83</td>
                  <td>% with chemotherapy dose delays (≥7 days)</td>
                  <td>De Boer RH <em>et al</em>. Eur J Cancer 2008;6(suppl):128 (abstract 269)</td>
               </tr>
               <tr>
                  <td>135</td>
                  <td>% with FN</td>
                  <td>Burstein HJ <em>et al</em>. J Clin Oncol 2005;23:8340-7.</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col">TAC</td>
                  <td>279<br />(93 with breast cancer)</td>
                  <td>Duration of grade 4 neutropenia in cycle 1</td>
                  <td>Burris HA <em>et al</em>. J Oncol Pract 2010;6:133–40.</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_first_col" rowspan="2">Various</td>
                  <td>852<br />(185 with breast cancer)</td>
                  <td>Incidence of FN across all cycles</td>
                  <td>Balducci L <em>et al</em>. Oncologist 2007; 12:1416-24</td>
               </tr>
               <tr>
                  <td>2249<br />(971 with breast cancer)</td>
                  <td>Incidence of neutropenic hospitalisations and chemotherapy dose delays or reductions</td>
                  <td>Ozer H <em>et al</em>. Oncologist 2007; 12:484-94</td>
               </tr>
               <tr>
                  <td class="body_of_evidence_popup_bottom_left">&nbsp;</td>
                  <td class="body_of_evidence_popup_total_col">&gt3000<br />total</td>
                  <td>&nbsp;</td>
                  <td>&nbsp;</td>
               </tr>
            </table>
         </div>
       </div>
    </div>
    <!-- Strong PopUp 4 Ends -->
    <!-- Strong PopUp 5 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_sclc">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 5 Header">SCLC <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 5 Table Header">
            <tr>
               <th width="245">Investigated regimen(s)<br />(among others)</th>
               <th width="93">No. in study</th>
               <th width="285">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 5 Table">
            <tr>
               <td width="253" class="body_of_evidence_popup_first_col">ACE</td>
               <td width="95">30</td>
               <td width="280">% receiving cycle-2 chemotherapy at full dose and on schedule</td>
               <td width="127">Pirker R <em>et al</em>. Lung 2006;184:279-85</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col">Various</td>
               <td>2249<br />(76 SCLC)</td>
               <td>Incidence of neutropenic hospitalisations and chemotherapy dose delays or reductions</td>
               <td>Ozer H <em>et al</em>. Oncologist 2007; 12:484-94</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_bottom_left">&nbsp;</td>
               <td class="body_of_evidence_popup_total_col">&gt100<br />total</td>
               <td>&nbsp;</td>
               <td>&nbsp;</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 5 Ends -->
    <!-- Strong PopUp 6 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_ovarian">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 6 Header">Ovarian <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 6 Table Header">
            <tr>
               <th width="245">Investigated regimen(s)<br />(among others)</th>
               <th width="91">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 6 Table">
            <tr>
               <td width="232" class="body_of_evidence_popup_first_col">Topotecan</td>
               <td width="91">279 <br />(21 with ovarian)</td>
               <td width="296">Duration of severe (grade 4) neutropenia in cycle 1</td>
               <td width="136">Burris HA <em>et al</em>. J Oncol Pract 2010; 6:133-40</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col">Carboplatin/paclitaxel</td>
               <td>61 <br />(19 with ovarian)</td>
               <td>Peak peripheral CD34+ cell count in cycle 1</td>
               <td>Willis F <em>et al</em>.  Bone Marrow Transplant. 2009; 43:927-34</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_first_col" rowspan="2">Various</td>
               <td>852<br />(118 with ovarian)</td>
               <td>Incidence of FN</td>
               <td>Balducci L <em>et al</em>.  Oncologist 2007; 12:1416-24</td>
            </tr>
            <tr>
               <td>2249<br />(161 with ovarian)</td>
               <td>Incidence of neutropenic hospitalisations and chemotherapy dose delays or reductions</td>
               <td>Ozer H <em>et al</em>. Oncologist 2007; 12:484-94</td>
            </tr>
            <tr>
               <td class="body_of_evidence_popup_bottom_left">&nbsp;</td>
               <td class="body_of_evidence_popup_total_col">&gt300<br />total</td>
               <td>&nbsp;</td>
               <td>&nbsp;</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 6 Ends -->
    <!-- Strong PopUp 7 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_colorectal">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 7 Header">Colorectal Cancer <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 7 Table Header">
            <tr>
               <th width="245">Investigated regimen(s)<br />(among others)</th>
               <th width="91">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 7 Table">
            <tr>
               <td width="247" class="body_of_evidence_popup_first_col">FOLFOX4 or FOLFIRI or FOIL</td>
               <td width="93">252</td>
               <td width="283">Incidence of grade 3/4 neutropenia</td>
               <td width="132">Hecht JR <em>et al</em>. Clinical Colorectal Cancer 2010; 9(2):95–101</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 7 Ends -->
    <!-- Strong PopUp 8 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_paediatric">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 8 Header">Paediatric sarcoma <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 8 Table Header">
            <tr>
               <th width="245">Investigated regimen(s)<br />(among others)</th>
               <th width="91">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 8 Table">
            <tr>
               <td width="249" class="body_of_evidence_popup_first_col">VDC/IE</td>
               <td width="94">44</td>
               <td width="279">Duration of severe (grade 4) neutropenia during cycles 1 and 3</td>
               <td width="133">Spunt SL <em>et al</em>. J Clin Oncol 2010; 28:1329-36</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 8 Ends -->
    <!-- Strong PopUp 9 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_aml">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 9 Header">AML <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 9 Table Header">
            <tr>
               <th width="245">Investigated regimen(s)<br />(among others)</th>
               <th width="91">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 9 Table">
            <tr>
               <td width="230" class="body_of_evidence_popup_first_col">Idarubicin/cytarabine</td>
               <td width="98">84</td>
               <td width="288">Time to recovery from severe neutropenia</td>
               <td width="139">Sierra J <em>et al</em>. BMC Cancer 2008; 8:195</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 9 Ends -->
    <!-- Strong PopUp 10 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_myeloma">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title" data-ag-editable="Body of evidence Strong Popup 10 Header">Multiple myeloma <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top" data-ag-editable="Body of evidence Strong Popup 10 Table Header">
            <tr>
               <th width="245">Investigated regimen(s)<br />(among others)</th>
               <th width="91">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
         </table>
         <table width="755" border="0" cellspacing="0" cellpadding="0" data-ag-editable="Body of evidence Strong Popup 10 Table">
            <tr>
               <td width="253" class="body_of_evidence_popup_first_col">RAD</td>
               <td width="94">69</td>
               <td width="276">Maximum tolerated dose of lenalidomide, response to therapy</td>
               <td width="132">Knop S <em>et al</em>. Blood 2009; 113:4137-43</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Strong PopUp 10 Ends -->
    <!-- Weak PopUp 1 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_breast_weak">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title_weak" data-ag-editable="Body of evidence Weak Popup 1 Header">Breast cancer <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top_weak" data-ag-editable="Body of evidence Weak Popup 1 Table Header">
            <tr>
               <th style="width:217px;">Investigated regimen(s)<br />(among others)</th>
               <th width="83">No. in study</th>
               <th width="250">Primary endpoint</th>
               <th width="123">Reference</th>
            </tr>
            <tr>
               <td style="width:217px;" class="body_of_evidence_popup_first_col">AT</td>
               <td width="83">202</td>
               <td width="250">Duration of severe neutropenia<br/><br/>
                               The study demonstrated non inferiority of Lipegfilgrastim in duration of severe neutropenia
                             </td>
               <td width="123">Bondarenko <em>et al.</em> Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy BMC Cancer 2013, 13:386</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Weak PopUp 1 Ends -->
    <!-- Weak PopUp 2 Starts -->
    <div class="lightbox_data" id="body_of_evidence_popup_lung_weak">
       <div class="body_of_evidence_popup">
          <div class="body_of_evidence_popup_title_weak" data-ag-editable="Body of evidence Weak Popup 2 Header">Lung cancer (NSCLC) <span>X</span></div>
          <table width="755" border="0" cellspacing="0" cellpadding="0" class="body_of_evidence_popup_top_weak" data-ag-editable="Body of evidence Weak Popup 2 Table Header">
            <tr>
               <th width="245">Investigated regimen</th>
               <th width="91">No. in study</th>
               <th width="287">Primary endpoint</th>
               <th width="132">Reference</th>
            </tr>
            <tr>
               <td width="236" class="body_of_evidence_popup_first_col">Cisplatin/etoposide</td>
               <td width="100">375</td>
               <td width="288">Incidence of FN in cycle 1 (lipegfilgrastim vs placebo) - endpoint not met</td>
               <td width="131">Lipegfilgrastim EPAR 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002556/WC500148382.pdf</td>
            </tr>
         </table>
       </div>
    </div>
    <!-- Weak PopUp 2 Ends -->
    <!-- Reference Strong Information Starts -->
    <div class="lightbox_data" id="body_of_evidence_refs_strong">
       <div id="body_of_evidence_refs_strong_holder" class="main_content_style">
          <p><strong data-ag-editable="Body of evidence References Strong Title">References:</strong></p>
          <div data-ag-editable="Body of evidence References Strong List">
             <ol>
                <li>Gregory SA <em>et al</em>. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncology 2010; 7(7):297-308</li>
                <li>Knop S <em>et al</em>. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009; 113(18):4137-4143</li>
                <li>Neulasta<sup>®</sup>, Summary of Product Characteristics, July 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf</li>
             </ol>
          </div>
          <div class="references_abb_lists" data-ag-editable="Body of evidence References Strong Bottom Copy">
             <ul>
                <li><p><strong>AT</strong>doxorubicin / docetaxel</p></li>
                <li><p><strong>FEC 100</strong>5-fluorouracil / epirubicin / cyclophosphamide</p></li>
                <li><p><strong>CMF</strong>cyclophosphamide / methotrexate / 5-fluourouracil</p></li>
                <li><p><strong>AC&gt;T</strong>doxorubicin / cyclophosphamide followed by paclitaxel</p></li>
                <li><p><strong>TAC</strong>docetaxel / doxorubicin / cyclophosphamide</p></li>
                <li><p><strong>ACE</strong>doxorubicin / cyclophosphamide / etoposide</p></li>
                <li><p><strong>VDC</strong>vincristine / doxorubicin / cyclophosphamide</p></li>
                <li><p><strong>IE</strong>ifosfamide / etoposide</p></li>
                <li><p><strong>R-CHOP</strong>cyclophosphamide / doxorubicin / vincristine / prednisone / rituximab</p></li>
                <li><p><strong>CHOP</strong>cyclophosphamide / doxorubicin / vincristine / prednisone</p></li>
                <li><p><strong>ESHAP</strong>etoposide / methylprednisolone / cisplatin / cytarabine</p></li>
                <li><p><strong>ICE</strong>ifosfamide / carboplatin / etoposide</p></li>
                <li><p><strong>RAD</strong>lenalidomide / adriamycin / dexamethasone</p></li>
                <li><p><strong>BEACOPP</strong>bleomycin /etoposide / adriamycin / cyclophosphamide / vincristine / procarbazine / prednisone</p></li>
                <li><p><strong>FOLFOX</strong>folinic acid / 5- fluorouracil / oxaliplatin</p></li>
                <li><p><strong>FOLFIRI</strong>folinic acid / 5- fluorouracil  / irinotecan</p></li>
                <li><p><strong>FOIL</strong>folinic acid / 5- fluorouracil / oxaliplatin / irinotecan</p></li>
                <li><p><strong>SCLC</strong>small cell lung cancer</p></li>
                <li><p><strong>NSCLC</strong>non-small cell lung cancer</p></li>
                <li><p><strong>AML</strong>acute myeloid leukaemia</p></li>
                <li><p><strong>NHL</strong>non-Hodgkin’s lymphoma</p></li>
             </ul>
          </div>
       </div>
    </div>
    <!-- Reference Strong Information Ends -->
    <!-- Reference Weak Information Starts -->
    <div class="lightbox_data" id="body_of_evidence_refs_weak">
       <div class="main_content_style">
          <p><strong data-ag-editable="Body of evidence References Weak Title">Reference:</strong></p>
          <div data-ag-editable="Body of evidence References Weak List">
             <ol>
                <li>Lipegfilgrastim EPAR 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002556/WC500148382.pdf</li>
             </ol>
          </div>
       </div>
    </div>
    <!-- Reference Weak Information Ends -->
</article>